Neoleukin Therapeutics, Inc. (NLTX) Stock Analysis

Neoleukin Therapeutics, Inc. (NLTX) Healthcare & Pipeline Overview

Neoleukin Therapeutics, Inc. pioneers de novo protein therapeutics, focusing on immunotherapies for cancer, inflammation, and autoimmunity. Their lead candidate, NL-201, mimics interleukin cytokines to combat cancers like renal cell carcinoma and melanoma, positioning them in the competitive specialty drug market with innovative protein design technology.

What Is the Investment Thesis for NLTX?

Neoleukin Therapeutics presents a high-risk, high-reward investment opportunity within the biopharmaceutical sector. The company's innovative protein design technology and lead candidate, NL-201, offer potential for significant growth in the cancer immunotherapy market. A key value driver is the successful clinical development and regulatory approval of NL-201 for renal cell carcinoma and melanoma. Upcoming clinical trial results will be critical catalysts. However, the company's small market capitalization ($8.20M) and limited resources pose significant risks, particularly regarding funding and competition. The company's future success hinges on positive clinical data and strategic partnerships.

Based on FMP financials and quantitative analysis

NLTX Key Highlights

Neoleukin Therapeutics focuses on developing immunotherapies using protein design technology.

• The company's lead product candidate, NL-201, targets cancer by mimicking the activity of interleukin cytokines.
• Neoleukin Therapeutics was founded in 2003 and is headquartered in Seattle, Washington.
• The company changed its name from Aquinox Pharmaceuticals, Inc. in August 2019.
• Neoleukin Therapeutics has a market capitalization of $8.20M and a beta of 1.10.

Who Are NLTX's Competitors?

NLTX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are NLTX's Key Strengths?

Innovative protein design technology.

• Lead product candidate targeting significant unmet medical need.
• Experienced management team.
• Focus on a high-growth market segment.

What Are NLTX's Weaknesses?

Limited financial resources.

• Small number of employees.
• Dependence on a single lead product candidate.
• Early stage of development.

What Could Drive NLTX Stock Higher?

Clinical trial results for NL-201 in renal cell carcinoma.

• Clinical trial results for NL-201 in melanoma.
• Expansion of NL-201 clinical trials to additional cancer types.
• Potential strategic partnerships and licensing agreements.

What Are the Key Risks for NLTX?

Financial-distress signal — its Altman Z-Score of -1.97 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-37.9%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures for NL-201.
• Regulatory hurdles in obtaining approval for NL-201.
• Competition from larger pharmaceutical companies with more resources.
• Difficulty in securing funding to support research and development.

What Are the Growth Opportunities for NLTX?

• Expansion of NL-201 Clinical Trials: Neoleukin has the opportunity to expand the clinical trials for NL-201 to include additional cancer types beyond renal cell carcinoma and melanoma. This expansion could significantly increase the potential market size for NL-201. The timeline for this expansion depends on the success of ongoing trials and securing additional funding.
• Strategic Partnerships and Licensing Agreements: Neoleukin can pursue strategic partnerships and licensing agreements with larger pharmaceutical companies to accelerate the development and commercialization of its product candidates. These partnerships can provide Neoleukin with access to additional funding, expertise, and resources. The market for licensing agreements in the biopharmaceutical industry is highly active, with numerous deals occurring annually. Securing a partnership could provide a significant boost to Neoleukin's valuation and future prospects.
• Development of New Immunotherapies: Neoleukin's protein design technology platform allows for the development of new immunotherapies targeting a wide range of diseases beyond cancer, including inflammation and autoimmunity. Expanding its pipeline of product candidates can diversify Neoleukin's revenue streams and reduce its reliance on NL-201. The market for immunotherapies is experiencing rapid growth, driven by advancements in protein engineering and a better understanding of the immune system.
• Advancements in Protein Design Technology: Continued advancements in protein design technology could lead to the development of more effective and targeted immunotherapies. Neoleukin can invest in research and development to improve its protein design platform and create novel proteins with enhanced therapeutic activity. The market for protein engineering technologies is growing rapidly, driven by increasing demand for personalized medicine and targeted therapies.
• Regulatory Approval and Commercialization of NL-201: The successful regulatory approval and commercialization of NL-201 would be a major growth driver for Neoleukin. This would validate the company's protein design technology and establish Neoleukin as a player in the cancer immunotherapy market. The timeline for regulatory approval depends on the results of clinical trials and the review process by regulatory agencies such as the FDA. Commercialization would require significant investment in sales and marketing infrastructure.

What Are NLTX's Competitive Advantages?

• Proprietary protein design technology platform.
• Novel de novo protein therapeutics.
• Patent protection for NL-201 and other product candidates.
• Expertise in protein engineering and immunology.

What Does NLTX Do?

Founded in 2003 and headquartered in Seattle, Washington, Neoleukin Therapeutics, Inc. is a biopharmaceutical company dedicated to developing innovative immunotherapies. Originally named Aquinox Pharmaceuticals, Inc., the company rebranded in August 2019 to reflect its strategic shift towards protein design technology. Neoleukin's core focus lies in creating de novo proteins that mimic the therapeutic activity of naturally occurring cytokines, specifically interleukin (IL)-2 and IL-15. Their lead product candidate, NL-201, is designed to treat various cancers, including renal cell carcinoma and melanoma, by stimulating the body's immune system to target and destroy cancer cells. This novel approach aims to provide more effective and less toxic cancer treatments compared to traditional therapies. Neoleukin's research and development efforts are centered on leveraging its protein design platform to expand its pipeline of immunotherapeutic candidates for cancer, inflammation, and autoimmune diseases. The company's strategy involves preclinical and clinical development programs to advance its product candidates through regulatory approval and ultimately commercialization.

What Products and Services Does NLTX Offer?

• Develops immunotherapies for cancer.
• Utilizes protein design technology to create novel therapeutics.
• Focuses on creating de novo proteins that mimic the activity of cytokines.
• Lead product candidate is NL-201, targeting renal cell carcinoma and melanoma.
• Aims to provide more effective and less toxic cancer treatments.
• Conducts preclinical and clinical development programs.

How Does NLTX Make Money?

• Develops and patents novel protein therapeutics.
• Conducts clinical trials to demonstrate safety and efficacy.
• Seeks regulatory approval from agencies like the FDA.
• Potentially partners with larger pharmaceutical companies for commercialization.

What Industry Does NLTX Operate In?

Neoleukin Therapeutics operates within the competitive and rapidly evolving biopharmaceutical industry, specifically in the area of specialty and generic drug manufacturing. The industry is characterized by intense research and development, stringent regulatory requirements, and high levels of competition. Companies like Neoleukin are striving to develop novel therapies for cancer and other diseases, driven by increasing global healthcare expenditure and unmet medical needs. The market for cancer immunotherapies is experiencing significant growth, with projections estimating substantial expansion in the coming years. Neoleukin's success depends on its ability to differentiate its products through innovative protein design and demonstrate clinical efficacy.

Who Are NLTX's Key Customers?

• Patients with cancer, inflammation, and autoimmune disorders.
• Healthcare providers who prescribe and administer immunotherapies.
• Pharmaceutical companies interested in licensing or acquiring novel therapeutics.

Company Profile

Neoleukin Therapeutics, Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Seattle, US. The company is led by CEO Donna M. Cochener-Metcalfe. NLTX has traded publicly since 2014.

Return on equity for Neoleukin Therapeutics, Inc. stands at -37.9%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -37.5%, showing how much profit it generates from its asset base. A current ratio of 13.08 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -126.7%, the inverse of the P/E and a quick read on earnings relative to price.

NLTX Valuation & Market Position

With a $8.20M market cap, Neoleukin Therapeutics, Inc. sits in the micro-cap segment of the market.

Quarterly Financial Performance: Neoleukin Therapeutics, Inc.

Revenue for Neoleukin Therapeutics, Inc. came in at $0 during Jun 2026. The company recorded a net loss of $34.5M, with diluted EPS of $-1.53. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare.

Neoleukin Therapeutics, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -1.97 places it in the distress zone, a signal of elevated financial risk.

Neoleukin Therapeutics, Inc. has beaten Wall Street's EPS estimate in 6 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 72.0% below estimates on average.

The most recent 11 insider filings for Neoleukin Therapeutics, Inc. break down as 5 sales and 6 purchases. On net that is roughly 46K shares acquired (about $3.6M) — insiders putting money in tends to read as conviction.

NLTX Financials

NLTX Latest News

NLTX Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources